Strategies for Neuromuscular Blockade in Patients with Myotonic Dystrophy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F65269705%3A_____%2F15%3A00063246" target="_blank" >RIV/65269705:_____/15:00063246 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/15:00083686

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Strategies for Neuromuscular Blockade in Patients with Myotonic Dystrophy

Popis výsledku v původním jazyce

Myotonic dystrophy is a chronic, slowly progressing, highly variable, inherited multisystemic disease. It is characterized by wasting of the muscles, cataracts, heart conduction defects, endocrine changes, slow gastric and bowel emptying, and myotonia. Patients with myotonic dystrophy show myotonic responses to succinylcholine and neostigmine, and increased sensitivity to non-depolarising muscle relaxants. Sugammadex, a novel drug developed specifically for the rapid reversal of neuromuscular blockade induced by steroidal non-depolarising muscle relaxants, would be useful in patients with muscular disorders. The use of sugammadex was reported in a patient with myasthenia gravis and Huntington's disease. During 2012-2014 were reported successful use of sugammadex in some cases for caesarean section, for laparoscopic ovarian cystectomy and for urgent abdominal surgery. In this chapter we would like to present, based on best evidence, strategy of neuromuscular blockade for the patient with myotonic dystrophy. We will report physiology and pathophysiology of neuromuscular transmission and potentially suitable approaches for neuromuscular blocking agent use. We will especially focus on premedication, induction of anaesthesia, response to muscle relaxants, reverse of neuromuscular blockade, the crucial points of safe anaesthesiological care, and other perioperative triggers. Moreover we will discuss use of neuromuscular blockade and its reverse in patients with myotonic dystrophy undergoing some special surgeries - caesarean section, scoliosis surgery and general surgery. Patients with myotonia may have abnormal responses to anaesthetic agents. An increased sensitivity to non-depolarising muscle relaxants is described in patients with myotonic dystrophy. Anti-cholinesterase drugs (neostigmine) can lead to myotonic reaction.

Název v anglickém jazyce

Strategies for Neuromuscular Blockade in Patients with Myotonic Dystrophy

Popis výsledku anglicky

Myotonic dystrophy is a chronic, slowly progressing, highly variable, inherited multisystemic disease. It is characterized by wasting of the muscles, cataracts, heart conduction defects, endocrine changes, slow gastric and bowel emptying, and myotonia. Patients with myotonic dystrophy show myotonic responses to succinylcholine and neostigmine, and increased sensitivity to non-depolarising muscle relaxants. Sugammadex, a novel drug developed specifically for the rapid reversal of neuromuscular blockade induced by steroidal non-depolarising muscle relaxants, would be useful in patients with muscular disorders. The use of sugammadex was reported in a patient with myasthenia gravis and Huntington's disease. During 2012-2014 were reported successful use of sugammadex in some cases for caesarean section, for laparoscopic ovarian cystectomy and for urgent abdominal surgery. In this chapter we would like to present, based on best evidence, strategy of neuromuscular blockade for the patient with myotonic dystrophy. We will report physiology and pathophysiology of neuromuscular transmission and potentially suitable approaches for neuromuscular blocking agent use. We will especially focus on premedication, induction of anaesthesia, response to muscle relaxants, reverse of neuromuscular blockade, the crucial points of safe anaesthesiological care, and other perioperative triggers. Moreover we will discuss use of neuromuscular blockade and its reverse in patients with myotonic dystrophy undergoing some special surgeries - caesarean section, scoliosis surgery and general surgery. Patients with myotonia may have abnormal responses to anaesthetic agents. An increased sensitivity to non-depolarising muscle relaxants is described in patients with myotonic dystrophy. Anti-cholinesterase drugs (neostigmine) can lead to myotonic reaction.

Druh

C - Kapitola v odborné knize

CEP obor

FH - Neurologie, neurochirurgie, neurovědy

OECD FORD obor

—

Projekt

<a href="/cs/project/NT13906" target="_blank" >NT13906: Moderní postup myorelaxace a zvratu nervosvalové blokády při celkové anestezii u císařského řezu</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Myotonic dystrophies: epidemiology, diagnosis and therapeutic challenges

ISBN

978-1-63482-905-2

Počet stran výsledku

11

Strana od-do

1-11

Počet stran knihy

198

Název nakladatele

Nova Science Publishers, Inc.

Místo vydání

New York

Kód UT WoS kapitoly

—